Key facts
- Notable investors include Vento.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Alceus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Alceus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alceus Bio
Developer of synthetic chimeric antigen receptor T lymphocyte therapies intended to treat solid cancers. The company offers methods to extend the functional persistence of chimeric antigen receptor T lymphocytes in a controlled manner, targeting resistance mechanisms and modifying the tumor microenvironment through synthetic payloads, enabling researchers and clinicians to address challenges in solid tumor treatment.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- alceus.bio/
- Ownership
- Privately Held (backing)
Alceus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alceus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alceus Bio in its N-PORT filings yet. We sweep new filings monthly.